Laurus Labs Limited
LAURUSLABS
Classement en actions
#1744
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited,... Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
Prix de l'action
$22.83
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$12.34B
Changement (1 jour)
0.51%
Changement (1 an)
117.95%
Pays
IN
Échange Laurus Labs Limited (LAURUSLABS)
Catégorie
Healthcare
Bénéfices pour Laurus Labs Limited (LAURUSLABS)
Bénéfices en Jun 2026 TTM : $158.77M
Selon les derniers rapports financiers de Laurus Labs Limited, les bénéfices actuels de l'entreprise sont de $158.77M. En 2024, l'entreprise a réalisé un bénéfice de $27.63M, une diminution par rapport à celui de 2023 qui était de $134.55M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Laurus Labs Limited de 2013 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $158.77M | 178.14% |
| 2025 | $57.08M | 106.57% |
| 2024 | $27.63M | -79.46% |
| 2023 | $134.55M | -5.75% |
| 2022 | $142.76M | -19.68% |
| 2021 | $177.74M | 356.04% |
| 2020 | $38.97M | 126.00% |
| 2019 | $17.25M | -52.71% |
| 2018 | $36.46M | 0.99% |
| 2017 | $36.11M | 41.84% |
| 2016 | $25.45M | 137.71% |
| 2015 | $10.71M | -3.94% |
| 2014 | $11.15M | -29.65% |
| 2013 | $15.85M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,011.36% |
IN
|
